STICH3C: Comparing CABG and PCI for Heart Conditions
The STICH3C study is looking at two ways to treat severe coronary artery disease (blocked heart arteries) and heart failure (when your heart can't pump enough blood). It compares revascularization by PCI (Percutaneous Coronary Intervention, a procedure to open blocked arteries with a balloon and stent) with revascularization by CABG (Coronary Artery Bypass Grafting, a surgery to create new paths for blood flow around blocked arteries). The study aims to see which treatment is better at reducing the risk of death, stroke, heart attack, needing another procedure, or being readmitted for heart failure over about 5 years. You might be able to join if you are over 18, have a reduced heart pumping ability (LVEF ≤40%), and have significant blockages in multiple heart arteries. The study is currently recruiting participants.
- Study design
- This is an international study involving 754 participants who will be randomly assigned to receive either PCI or CABG. It is an unblinded study, meaning both you and your doctors will know which treatment you receive.
- What's involved
- Initial treatment is expected within 2 weeks of joining, with some procedures possibly staged over 90 days. The study will follow you for about 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for a median of 5 years after their treatment to track their health outcomes.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
At a glance
Conditions
Where it's being run
43 sites across 28 statesStudy leadership
- Stephen Fremes, MD,MSc,FRCSC · PRINCIPAL_INVESTIGATOR · Sunnybrook Health Sciences Center, Toronto, Canada
- Mario Gaudino, MD,PhD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University, USA
- Jean L Rouleau, MD,PhD · PRINCIPAL_INVESTIGATOR · Montreal Heart Institute, QC Canada
- Guillaume Maquis-Gravel, MD,MSc · PRINCIPAL_INVESTIGATOR · Montreal Heart Institute, QC Canada
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The Primary outcome is a Composite of all-cause mortality, stroke, spontaneous myocardial infarction, urgent repeat revascularization or heart failure readmission.Median follow-up of 5 years.
Time to event outcome measured as the time from randomization to the occurence of the first event.